SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-22-023505
Filing Date
2022-06-21
Accepted
2022-06-21 19:49:41
Documents
1
Period of Report
2022-06-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4076
  Complete submission text file 0000899243-22-023505.txt   5479
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39661 | Film No.: 221029605

Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Issuer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences